End Of Road For ‘Too Complex’ EU Pilot On Splitting Marketing Licenses
Executive Summary
EU regulators have pulled the plug on a pilot program on splitting mutual recognition and decentralized procedure licences. Instead of promoting harmonization of marketing authorizations across the EU and helping companies with their marketing strategies, it has led to more problems.
You may also be interested in...
EU Extends Pilot On Splitting Mutual Recognition/Decentralized Procedures
Drug companies in the EU are getting more time to experiment with splitting their mutual recognition and decentralized procedure licences to help with their marketing strategies.
EU To Test Merging & Splitting Of Licences Under Mutual Recognition/Decentralized Procedures
The CMDh - the EU group that co-ordinates the approval of human medicines evaluated through the mutual recognition and decentralized procedures - has launched a pilot project that will allow drug companies to merge or split MRP/DCP lines to suit their business strategies1.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.